Any announcements will probably come from C C's: Bio Ceo & Investors Conference Feb, Cowen & Co Healthcare Conference in March, Annual Report in March, Needham Healthcare Conference in April. It's not likely that there will be any disappointments at any of these C C's, because Uli has left a lot of slack in his timeline for the NDA, so any improvement in the timeline will be very positive
If i remember correctly, ACAD is scheduled to meet with the FDA this Spring. I hope the meeting will result in an announcement that FDA agrees to rolling submission of the NDA, starting immediately and finishing with stability data in late 2014. Perhaps allowing accelerated NDA approval in early 2015.
that would be a nice outcome. For those of you who like the area of research in which ACAD is engaged, you might consider looking at ARNA. They have an approved product and are well off the recent highs.